Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
Ananda CEO outlines progress with trials, strengthened structure and improved investor sentiment
MP3•Beranda episode
Manage episode 431272064 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Ananda Developments CEO Melissa Sturgess discussed the company's recent advancements in CBD-based drug development with Proactive's Stephen Gunnion. Sturgess highlighted the progress of its clinical trials and the increasing understanding of CBD's potential in the pharmaceutical industry. She also discussed the growing distinction between over-the-counter CBD products and those being developed by Ananda, emphasising the regulatory pathway necessary for CBD medicines. Sturgess highlighted two phase two clinical trials, focusing on chemotherapy-induced pain and endometriosis, initiated by clinicians responding to patient needs. She explained the challenges and benefits of getting CBD drugs approved by the MHRA and available on the NHS, aiming to make these drugs accessible to all patients. Discussing the company's portfolio, Sturgess shared insights on their pre-clinical study using MRX1 in mice and the importance of breadth and depth in the company's research. She also talked about strengthening the company's top structure with the appointment of a scientific advisory board, chaired by Professor Clive Page, and new members, Professors Trevor Jones and Cherry Wainwright. Sturgess concluded by outlining the milestones shareholders should look for, including clinical trial progress and further study results. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AnandaDevelopments #CBDDrugs #ClinicalTrials #MelissaSturgess #Pharmaceuticals #CBDResearch #MHRA #NHS #InvestingInPharma #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episode
MP3•Beranda episode
Manage episode 431272064 series 2891889
Konten disediakan oleh Proactive Investors. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Proactive Investors atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Ananda Developments CEO Melissa Sturgess discussed the company's recent advancements in CBD-based drug development with Proactive's Stephen Gunnion. Sturgess highlighted the progress of its clinical trials and the increasing understanding of CBD's potential in the pharmaceutical industry. She also discussed the growing distinction between over-the-counter CBD products and those being developed by Ananda, emphasising the regulatory pathway necessary for CBD medicines. Sturgess highlighted two phase two clinical trials, focusing on chemotherapy-induced pain and endometriosis, initiated by clinicians responding to patient needs. She explained the challenges and benefits of getting CBD drugs approved by the MHRA and available on the NHS, aiming to make these drugs accessible to all patients. Discussing the company's portfolio, Sturgess shared insights on their pre-clinical study using MRX1 in mice and the importance of breadth and depth in the company's research. She also talked about strengthening the company's top structure with the appointment of a scientific advisory board, chaired by Professor Clive Page, and new members, Professors Trevor Jones and Cherry Wainwright. Sturgess concluded by outlining the milestones shareholders should look for, including clinical trial progress and further study results. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AnandaDevelopments #CBDDrugs #ClinicalTrials #MelissaSturgess #Pharmaceuticals #CBDResearch #MHRA #NHS #InvestingInPharma #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episode
همه قسمت ها
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.